Quest Diagnostics (NYSE:DGX) Price Target Raised to $145.00

Quest Diagnostics (NYSE:DGX – Get Free Report) had its target price boosted by investment analysts at Citigroup from $135.00 to $145.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup’s target price suggests a potential upside of 5.27% from the company’s previous […]

Related Keywords

United States ,Vickyb Gregg ,Leerink Partnrs ,Catherinet Doherty ,Jefferies Financial Group ,Visionpoint Advisory Group ,Quest Diagnostics ,Quest Diagnostics Company Profile ,Citigroup ,Securities Inc ,Wealth Management ,Quest Diagnostics Incorporated ,Altshuler Shaham Ltd ,Get Free Report ,Financial Group ,Director Vicky ,Shaham Ltd ,Point Advisory Group ,Spartan Planning ,Diagnostics Incorporated ,Quest Diagnostics Daily ,Nyse Dgx ,Dgx ,Medical ,74834l10 ,Boost Price Target ,Citigroup Inc ,